Emerging treatments
Solithromycin
Solithromycin, an investigational fluoroketolide antibiotic, was evaluated in a phase 3 in vitro study against azithromycin.[76] It demonstrated higher intracellular potency than azithromycin against Legionella pneumophila serogroup 1. The US Food and Drug Administration (FDA) requested additional studies with more patients to ensure that serious liver injury is not a risk, but no further trials have been conducted.
Lefamulin
Lefamulin is a first-in-class pleuromutilin antibiotic approved by the FDA for the treatment of adults with community-acquired pneumonia caused by susceptible micro-organisms.[77] One phase 3 randomised clinical trial concluded that, among patients with community-acquired bacterial pneumonia, a 5-day course of oral lefamulin was non-inferior to a 7-day course of oral moxifloxacin with respect to early clinical response at 96 hours after the first dose.[78]
Use of this content is subject to our disclaimer